EA018974B9 - Твердые лекарственные формы - Google Patents

Твердые лекарственные формы

Info

Publication number
EA018974B9
EA018974B9 EA201070713A EA201070713A EA018974B9 EA 018974 B9 EA018974 B9 EA 018974B9 EA 201070713 A EA201070713 A EA 201070713A EA 201070713 A EA201070713 A EA 201070713A EA 018974 B9 EA018974 B9 EA 018974B9
Authority
EA
Eurasian Patent Office
Prior art keywords
solid state
androstane
ethynyl
diol
formulations
Prior art date
Application number
EA201070713A
Other languages
English (en)
Other versions
EA018974B1 (ru
EA201070713A1 (ru
Inventor
Стивен К. Вайт
Двайт Стикни
Эрин Олсон
Кейт Р. Лоример
Брентон С. Вулф
Original Assignee
Харбор Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Харбор Терапьютикс, Инк. filed Critical Харбор Терапьютикс, Инк.
Publication of EA201070713A1 publication Critical patent/EA201070713A1/ru
Publication of EA018974B1 publication Critical patent/EA018974B1/ru
Publication of EA018974B9 publication Critical patent/EA018974B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

В изобретении предложен и рассмотрен твердый 17α-этинил-5α-андростан-3α,17β-диол, в том числе его аморфные и кристаллические формы и конкретные полиморфные формы. Дегидраты и сольваты 17α-этинил-5α-андростан-3α,17β-диола включают дегидрат в форме III и сольват в форме I. Изобретение также относится к твердым и суспензионным составам, содержащим 17α-этинил-5α-андростан-3α,17β-диол в описанной твердой форме, и применению этих составов для лечения у субъектов или пациентов-людей раков или предраковых состояний, таких как рак предстательной железы или рак молочной железы. Изобретение также относится к способам получения жидких составов из твердых форм 17α-этинил-5α-андростан-3α,17β-диола и применению таких составов при лечении описанных состояний.
EA201070713A 2008-02-05 2009-02-05 Твердые лекарственные формы EA018974B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US9369408P 2008-09-02 2008-09-02
PCT/US2009/033280 WO2009100258A1 (en) 2008-02-05 2009-02-05 Pharmaceutical solid state forms

Publications (3)

Publication Number Publication Date
EA201070713A1 EA201070713A1 (ru) 2011-08-30
EA018974B1 EA018974B1 (ru) 2013-12-30
EA018974B9 true EA018974B9 (ru) 2014-04-30

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070713A EA018974B9 (ru) 2008-02-05 2009-02-05 Твердые лекарственные формы

Country Status (11)

Country Link
US (4) US8518922B2 (ru)
EP (1) EP2249838A4 (ru)
JP (1) JP2011511011A (ru)
KR (1) KR20100113602A (ru)
CN (2) CN103467554A (ru)
AU (1) AU2009212314C1 (ru)
CA (1) CA2712005C (ru)
EA (1) EA018974B9 (ru)
HK (1) HK1147695A1 (ru)
IL (1) IL207378A0 (ru)
WO (1) WO2009100258A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252947B2 (en) * 2008-04-03 2012-08-28 Harbor Therapeutics, Inc. Solid state forms of a pharmaceutical
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
CA2787027A1 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Detection of gastrointestinal disorders
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
WO2012083161A1 (en) * 2010-12-17 2012-06-21 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
CA2930199C (en) * 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
EP3353148A4 (en) 2015-09-25 2019-04-24 Context Biopharma Inc. PROCESS FOR THE PRODUCTION OF ONAPRISTONE INTERMEDIATE PRODUCTS
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
EP3888021B1 (en) 2018-11-30 2024-02-21 Caris MPI, Inc. Next-generation molecular profiling
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
EP4069865A4 (en) 2019-12-02 2023-12-20 Caris MPI, Inc. PLATINUM RESISTANCE TEST FOR PAN CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224932A1 (en) * 2000-08-05 2004-11-11 Keith Biggadike Novel anti-inflammatory androstane derivative compositions
US20070129548A1 (en) * 2005-12-07 2007-06-07 Lushi Tan Polymorphs of an androgen receptor modulator
US20080021006A1 (en) * 1999-09-30 2008-01-24 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical Compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) * 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
AU4841193A (en) * 1992-08-28 1994-03-29 Lunar Corporation 1alpha,24(S)-dihydroxy vitamin D2, its formation and use
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
ATE340173T1 (de) 1996-03-29 2006-10-15 Duphar Int Res Piperazin- und piperidin- derivate
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
DE60114467T2 (de) * 2000-12-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Zubereitungen enthaltend ein steroidhormon und ein stabilisierungsmittel in nicht-kristalliner form
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
DK2486924T3 (en) * 2006-04-22 2019-03-04 Neurmedix Inc Medicines and uses
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080021006A1 (en) * 1999-09-30 2008-01-24 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical Compositions
US20040224932A1 (en) * 2000-08-05 2004-11-11 Keith Biggadike Novel anti-inflammatory androstane derivative compositions
US20070129548A1 (en) * 2005-12-07 2007-06-07 Lushi Tan Polymorphs of an androgen receptor modulator

Also Published As

Publication number Publication date
US20130338125A1 (en) 2013-12-19
IL207378A0 (en) 2010-12-30
CA2712005A1 (en) 2009-08-13
EA018974B1 (ru) 2013-12-30
AU2009212314B2 (en) 2013-11-21
CN101939009A (zh) 2011-01-05
US9314471B2 (en) 2016-04-19
EP2249838A1 (en) 2010-11-17
JP2011511011A (ja) 2011-04-07
US20090291932A1 (en) 2009-11-26
CA2712005C (en) 2014-04-15
AU2009212314A1 (en) 2009-08-13
KR20100113602A (ko) 2010-10-21
WO2009100258A1 (en) 2009-08-13
CN103467554A (zh) 2013-12-25
AU2009212314C1 (en) 2014-05-08
CN101939009B (zh) 2013-07-17
HK1147695A1 (en) 2011-08-19
US8518922B2 (en) 2013-08-27
US20130345455A1 (en) 2013-12-26
EA201070713A1 (ru) 2011-08-30
EP2249838A4 (en) 2012-05-02
US20130345184A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
EA018974B9 (ru) Твердые лекарственные формы
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
HK1169321A1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
TN2012000171A1 (en) Synthetic methods for spiro-oxindole compounds
PH12014502133A1 (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
SG10201811480WA (en) Therapeutic compounds and compositions
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
EP2523678A4 (en) WNT ANTAGONISTS AND METHODS OF TREATMENT AND SCREENING
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
WO2009151598A8 (en) Diazacarbazoles and methods of use
MX2009013321A (es) Derivados de espiro[piperidin-4,4'-tieno[3,2-c]pirano] y compuestos relacionados como inhibidores del receptor sigma para el tratamiento de psicosis.
SG171583A1 (en) Composition for the treatment of resistant cancers comprising oridonin
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2010099003A3 (en) Compositions and methods for visualizing and eliminating cancer stem cells
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
IL195969A0 (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
MX2010013608A (es) Pirroles sustituidos y metodos de uso.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU